Paper Details

  1. Home
  2. Paper Details

Design and in vitro assessment of chitosan nanocapsules for the pulmonary delivery of rifabutin.

Author: AlrabadiNasr, CsabaNoemi, HaddadRazan, Remuñán-LópezCarmen, SánchezSandra, Valverde-FragaLorena

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

This study aimed to develop a nanosystem for the improved delivery of rifabutin, an antibiotic used to treat tuberculosis (TB). The nanosystem consists of a chitosan shell and a lipid core, which allows for optimal association of the hydrophobic drug rifabutin. The nanocapsules demonstrated safety and efficient internalization in vitro, and complete inhibition of Mycobacterium phlei at antibiotic concentrations within the expected susceptibility range.
Paper Details　
Original Abstract of the Article :
Tuberculosis (TB) is a life-threatening disease and a main cause of death worldwide. It mainly affects the lungs, and it is attributed to the infection with Mycobacterium tuberculosis (MTB). Current treatments consist of the oral administration of combinations of antibiotics including rifabutin, in ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.ejps.2023.106484

データ提供：米国国立医学図書館（NLM）

Chitosan Nanocapsules: A Novel Delivery System for Rifabutin in Tuberculosis Treatment

Tuberculosis (TB) remains a significant global health concern, with the need for more effective and well-tolerated treatment options. This research explores the potential of chitosan nanocapsules as a novel delivery system for rifabutin, a common antibiotic used to treat TB. The study investigates the development and characterization of these nanocapsules, evaluating their ability to deliver rifabutin effectively while minimizing side effects.

Chitosan Nanocapsules: Improving Rifabutin Delivery for Enhanced TB Treatment

This research presents a promising approach to improving rifabutin delivery, potentially leading to more effective and safer treatment for TB. The study demonstrates the effectiveness of chitosan nanocapsules in encapsulating rifabutin and delivering it to target cells, potentially improving drug efficacy and reducing the need for high doses.

Chitosan Nanocapsules: A New Frontier in TB Treatment

This research offers a glimpse into the future of TB treatment, highlighting the potential of nanotechnology to enhance drug delivery and improve patient outcomes. The study's findings suggest that chitosan nanocapsules could offer a significant advancement in TB treatment, providing a more effective and well-tolerated approach to combating this devastating disease.

Dr.Camel's Conclusion

Just as a camel navigates the vast and challenging desert, this research explores a new path for TB treatment. Chitosan nanocapsules offer a potential oasis for improving rifabutin delivery, allowing for more effective and efficient treatment of this disease. This research provides a glimmer of hope for a more manageable journey through the desert of TB, leading to improved outcomes for patients.

Date :
  1. Date Completed 2023-06-21
  2. Date Revised 2023-06-21
Further Info :

Pubmed ID

37268092

DOI: Digital Object Identifier

10.1016/j.ejps.2023.106484

Related Literature

Article Analysis
・Effects of rifabutin
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.